Hormonal
Lifestyle modification and metformin treatment can modulate gut microbiota and maintain glucose homeostasis in type 2 diabetes, suggesting similar potential for post-GDM women.
For post-GDM women, lifestyle changes and metformin have been shown to help manage blood sugar and potentially improve gut bacteria. However, adherence to lifestyle changes is often poor after delivery, and metformin's use as a preventive strategy is still debated. Prioritize sustainable lifestyle habits.
Lifestyle modification and pharmacological treatment with metformin showed evidence of modulation of gut microbiota and proved to be beneficial to maintain glucose homeostasis in T2DM.
Why this rating
Cited as established evidence in T2DM, though the paper notes compliance and controversy in post-GDM women.
Source
Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential
Zubaidah Hasain et al. · Frontiers in Cellular and Infection Microbiology · 2020
DOI 10.3389/fcimb.2020.00188
More from this paper
- Gut microbiota dysbiosis, characterized by elevated pathobionts (e.g., Proteobacteria, Enterobacteriaceae) and depleted beneficial bacteria (e.g., Faecalibacterium, Bifidobacterium), is associated with gestational diabetes mellitus (GDM) and postpartum glucose intolerance, potentially serving as a predictive biomarker for type 2 diabetes.Moderate
- Gut microbiota dysbiosis in GDM involves elevated lipopolysaccharide (LPS) production and translocation, leading to low-grade inflammation and insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →